linjc16/ctgov huggingface dataset:
Visual Study of Molecular Genotype in Glioma Evolution

Study Overview
=================
Brief Summary
-----------------
The key molecular changes in the progression of glioma are closely related to tumor heterogeneity, pathological grade, precision treatment and prognosis of glioma. At present, a visually quantitative assessment criteria about the key molecular typing of glioma is still absent. Based on the previous research, this project intends to establish a multi-dimensional database of glioma from clinical, radiomics and microomics levels. The investigators aim to filter out the specific molecular markers in the progression of glioma and explore the intrinsic connection of radiomics features and microomics molecular markers by using bioinformatics integration analysis and artificial intelligence multiple kernel learning. Thus, the investigators could determine the specific molecular mechanism in the progression of glioma, and establish a visually quantitative assessment system of pre-operative precisive grading, molecular typing discrimination and prognosis prediction. The completion of this project is of great significance for improving molecular diagnostic level of glioma, guiding individualized diagnosis and treatment decisions, and improving the survival rate of patients.

Official Title
-----------------
A New Strategy for the Visulation of Molecular Genotype in Glioma Evolution Based on the Radiomics and Microomics

Conditions
-----------------
Glioma of Brain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: postoperative pathological and genetic test confirmed brain glioma; The preoperative Clear and complete multimodal imaging data were collected within 10 days. Exclusion Criteria: patients who underwent surgery more than 4 weeks after MRI; patients with motion artifacts.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| radiomics features（the parameters of T1WI, T2WI, DWI, DKI, ASL, ESWAN, DCE, MRS and so on） | the radiomics features（the parameters of T1WI, T2WI, DWI, DKI, ASL, ESWAN, DCE, MRS and so on）in the progression of glioma | through study completion, an average of 3 years | 
| microomics molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features) | the key molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features) in the progression of glioma | through study completion, an average of 3 years |
Sexual Needs of Adolescents Living With HIV Since Childhood

Study Overview
=================
Brief Summary
-----------------
To improve the knowdelge about the sexual health needs of perinatally HIV-infected adolescents living in France.

Detailed Description
-----------------
20 individual semi-structured interviews will be conducted with 20 young adults living with HIV sinc childhood and living in France. The aim of this study is to identify their sexual needs through exploring their personal experience of sexuality during their adolescence. The investigator intend to explore communication about the disease and sexuality within their families ; communication about sexual health with health care professionnals ; whether sexuality has arrose difficulties related to their chronic condition such as rejection or sadness ; whether there are differences in sexual needs regarding gender. A thematic analysis will be conducted by three researchers.

Official Title
-----------------
Sexual Health Needs of Adolescents Living With HIV Since Childhood : a Qualitative Study

Conditions
-----------------
Hiv, Perinatal HIV Infection

Intervention / Treatment
-----------------
* Other: Interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 25 yo HIV-1 or HIV-2 diagnosis before the age of 13 non opposition to participate to the study be affiliated to a social security scheme (except Aide Médicale de l'Etat (AME)) Exclusion Criteria: having contracted HIV infection through sexual contact persons under guardianship or custodianship, or deprived of their liberty by a judicial or administrative decision associated illnesses or disabilities that makes participation impossible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adolescents with perinatal acquired HIV infection<br>group of Adolescents with perinatal acquired HIV infection | Other: Interview<br>* Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative analysis | emerging themes describing the experience of their sexual health needs from the content analysis of the transcribed interviews | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, sexual Health, adolescent, sexual needs
Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics

Study Overview
=================
Brief Summary
-----------------
Changes in prescribing will be compared in prescribers from specialties whose prescribing is hypothesized to be relatively unaffected by the REMS (such as oncologists and hospice providers) versus those for whom the REMS could have greater impact on prescribing (e.g., dentists). Trends and changes in monthly prescription volume and average monthly prescription volume will be evaluated by prescriber specialty.

Conditions
-----------------
Opioid Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse

Intervention / Treatment
-----------------
* Other: Non-interventional study - retrospective database review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Changes in number of prescriptions for prescriber types with less or more compelling reasons to prescriber ER/LA opioid analgesics Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pain<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| PCP<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Dentist<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Surgery<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Emergency Medicine<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Oncology<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Hospice and Palliative Medicine<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Anesthesiology<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Neurology<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Nurse Practitioners<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Pediatrics<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Physical Medicine & Rehabilitation<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Physician Assistant<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| Rheumatology<br> | Other: Non-interventional study - retrospective database review<br> <br> |
| All Other Specialties<br> | Other: Non-interventional study - retrospective database review<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Monthly volume of prescriptions by specialty |  | July 2010-December 2014 |
3TC or No 3TC for HIV With 3TC Resistance

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effects of continuing or discontinuing 3TC treatment in the presence of HIV virus with 3TC resistance for persons who are on a regimen including least three other anti-HIV drugs. The overall aim is to determine whether continuing 3TC is of benefit in HIV-positive persons who have already shown resistance to this drug.

Official Title
-----------------
A Randomized Study to Evaluate Virologic Response Following Discontinuation vs. no Discontinuation of 3TC in Patients Who Are Infected With HIV With Previously Documented Reduced Susceptibility to 3TC and Who Have Adequate Virologic Suppression on Combination Antiretroviral Therapy

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Lamivudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be HIV positive Be at least 18 years old. Currently receiving 3TC for HIV infection in conjunction with at least three other antiretroviral drugs. Must have started this regimen at least three months prior to starting this study. A plasma viral load of less than 50 copies/mL on at least two occasions (measured at least 28 days apart immediately prior to screening). Evidence of resistance to 3TC Exclusion Criteria: Pregnancy or breastfeeding. Hepatitis B surface antigen (HbsAg) positive at time of screening or with the previous year.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lamivudine|See Detailed Description.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Virologic failure (VL above 50 copies/ml) on two consecutive dates, at least two weeks apart, in the absence of concurrent acute illness or recent immunization during the first 24 weeks. |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent and absolute change in viral load from baseline to week 24 and week 48. |  | 48 weeks | 
| Change in CD4 count in both absolute number and percentage from baseline to week 24 and week 48. |  | 48 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Treatment Experienced
Noninvasive Ventilatory Support After Lung Surgery in COPD Patients

Study Overview
=================
Brief Summary
-----------------
Rationale: respiratory complications are the most frequent complications following lung resection and represent a noticeable cause of mortality. Benefits from non-invasive ventilation (NIV) in acute respiratory failure are now clearly demonstrated. The use of preventive NIV after lung resection, in the absence of acute respiratory failure and/or hypercarbia, could be justified by the physiological benefits expected. The goal of this study is to assess the efficacy of post-operative NIV in moderate-to-severe COPD, for prevention of respiratory complications. Material and Methods: This is a prospective randomised multicenter trial with an open parallel design in moderate-t-o-severe COPD patients hospitalised in thoracic surgery for lung resection. Expected results: This study will determine whether post-operative NIV decreases the incidence of acute respiratory events (acute respiratory failure) and whether some subgroups of patients benefit more from this strategy. Conclusion: This study should help evaluating the utility of post-operative NIV after lung resection.

Official Title
-----------------
Noninvasive Ventilatory Support After Lung Surgery to Prevent Pulmonary Complications in COPD Patients

Conditions
-----------------
COPD, Post Pulmonary Resection

Intervention / Treatment
-----------------
* Procedure: non invasive ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with COPD (FEV1 pre-operative <80% and FEV1/CV<70%) Patients undergoig pulmonary resection Informed consent Exclusion Criteria: Apnea syndrom and chronic noninvasive support Post-operative extrarespiratory organ failure Inhability to follow study protocole Absence of medical coverage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: non invasive ventilation|non invasive ventilation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
DF4 Connector System Post-Approval Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate long-term performance of the DF4 Connector System. This evaluation is based on the number of DF4 lead-related complications occurring during the study compared to the number of leads enrolled in the study. The DF4 systems will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the DF4 Connector Systems. This study is conducted within Medtronic's post-market surveillance platform.

Official Title
-----------------
DF4 Connector System Post-Approval Study

Conditions
-----------------
Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements Subject is intended to be implanted or is within 30 days post-implant of a DF4 Connector System with a Medtronic DF4 lead used for a pacing, sensing and/or defibrillation application Exclusion Criteria: Subject who is, or will be inaccessible for follow-up at a study site Subject with exclusion criteria required by local law (Europe, Central Asia [ECA] only) Implant and follow-up data, including any adverse device effects and system modifications at implant through the time of enrollment are unavailable
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DF4 Lead Related Complication Rate | To demonstrate that the complication-free probability is greater than 92.5% at five years post-implant for the high voltage DF4 lead | Up to 5 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Types of DF4 lead related events | Number of DF4 lead related events grouped by type | Up to 5 years | 
| Bipolar pacing impedance (ohms) | Summary statistics at 5 years post-implant will be reported. | 5 years | 
| High voltage impedance (ohms) | Summary statistics at 5 years post-implant will be reported | 5 years | 
| Pacing threshold (volts) | The pacing threshold is the minimum electrical stimulus needed to consistently depolarize the heart outside of the heart's refractory period. Summary statistics at 5 years post-implant will be reported. | 5 years | 
| Sensing amplitude (millivolts) | The amplitude of the intrinsic cardiac electrical signals detected by electrodes on the defibrillator lead will be summarized at 5 years post-implant. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ICD, CRTD, DF4
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).

Conditions
-----------------
Advanced Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Degarelix
* Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC) Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment Exclusion Criteria: Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline. Participation in a clinical trial at baseline and during the follow-up period
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Degarelix<br> | Drug: Degarelix<br>* According to medical practice<br>* Other names: Firmagon®;|
| LHRH agonist<br> | Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)<br>* According to medical practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of urologist's knowledge of patients' medical history at the point of decision making and during Androgen Deprivation Therapy (ADT) | Measured by questionnaires by quantifying the frequency of urologists' entries | Up to 4 years | 
| Level of urologist's knowledge of patients' comorbidities at the point of decision making and during ADT | Measured by questionnaires by quantifying the frequency of urologists' entries | Up to 4 years | 
| Level of urologist's knowledge of patients' concomitant medications at the point of decision making and during ADT | Measured by questionnaires by quantifying the frequency of urologists' entries | Up to 4 years | 
| Level of urologist's knowledge of patients' risk factors at the point of decision making and during ADT | Measured by questionnaires by quantifying the frequency of urologists' entries | Up to 4 years |
Web-based Daily Care Training of Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
Purpose:Effect of web-based daily care training on the quality of life of caregivers of children with cerebral palsy. study design: Single-blind clinical trial. study population: Caregivers of children with cerebral palsy. Inclusion criteria: caregiver -Mother of a child with cerebral palsy who spent most time on child care- Children with cerebral palsy aged 4 to 12 years old living in Alborz province that clinical diagnosis of cerebral palsy registered in their clinical records. Moderate and severe cerebral palsy (gross motor function levels 3 to 5). caregiver have facilities and basic knowledge of using Internet (Declared access to the Internet at least one hour a week). exclusion criteria: taking care of two or more children with disability. participated in previous face to face training programs. Sample size: 100. Intervention: Web-based daily care training. intervention time: 12-week. Outcome of the study: the quality of life of caregivers

Detailed Description
-----------------
step1: web development and design development of educational content (4 weeks) Create a paper version of the site (2 weeks) Create a web-based version of the site (4 weeks) pilot study (6 weeks) step 2: RCT (12 weeks)

Official Title
-----------------
Ethics Committee of the University of Social Welfare and Rehabilitation Science

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Other: web-based daily care training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: caregiver_ Mother of a child with cerebral palsy who spent most time on child care Children with cerebral palsy aged 4 to 12 years old living in Alborz province that clinical diagnosis of cerebral palsy registered in their clinical records Moderate and severe cerebral palsy (gross motor function levels 3 to 5) caregiver have facilities and basic knowledge of using Internet (Declared access to the Internet at least one hour a week) Exclusion Criteria: taking care of two or more children with disability participated in previous training programs
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intervention<br>web-based daily care training 12 week interactive web based caring training education | Other: web-based daily care training<br>* 12 week interactive web based caring training education<br>|
| No Intervention: control<br>Previous therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life of caregivers |  | 3 months |